irpages2.eqs.com/websites/anno...


Annovis Bio's lead drug candidate, ANVS401, will be featured in a poster presentation: Positive Clinical Outcomes in Two Phase 2a Studies: ADAS-Cog in Alzheimer's and MDS-UPDRS in Parkinson's patients plus Markers of Toxic Cascade that Leads to Nerve Cell Death.

Previously, Annovis Bio reported that AD patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11); PD patients treated with ANVS401 showed statistically significant motor function improvement as measure by the MDS-UPDRS. Additionally, in a test that measures speed and accuracy, AD and PD patients both responded with a statistically significant increase in correctly coded fields. The company also measured inflammatory factors and found statistically significant lowering of these factors. These tests were part of the Company's ongoing Phase 2a study in AD and PD patients.